These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6850667)

  • 21. Phase II study of methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.
    Engstrom PF; Catalano RB; Creech RH
    Cancer Treat Rep; 1976 Mar; 60(3):285-7. PubMed ID: 1260784
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.
    Schell FC; Yap HY; Hortobagyi GN; Issell B; Esparza L
    Cancer Chemother Pharmacol; 1982; 7(2-3):223-5. PubMed ID: 7083463
    [No Abstract]   [Full Text] [Related]  

  • 23. Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation.
    Lazarus HM; Creger RJ; Diaz D
    Cancer Treat Rep; 1986 Jun; 70(6):819-20. PubMed ID: 3524832
    [No Abstract]   [Full Text] [Related]  

  • 24. [Etoposide in the treatment of recurrent malignant lymphoma].
    Háber J; Klener P
    Vnitr Lek; 1986 Apr; 32(4):379-85. PubMed ID: 3727425
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
    Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
    Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
    [No Abstract]   [Full Text] [Related]  

  • 26. VP-16-213. A phase II trial using a weekly schedule.
    Karp G; Antman K; Canellos G
    Cancer Clin Trials; 1981; 4(4):465-7. PubMed ID: 7318129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PHASE I clinical trial of an oral solution of VP-16-213.
    Nissen NI; Dombernowsky P; Hansen HH; Larsen V
    Cancer Treat Rep; 1976 Jul; 60(7):943-5. PubMed ID: 1009527
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study.
    Machover D; Schwarzenberg L; Goldschmidt E; Tourani JM; Michalski B; Hayat M; Dorval T; Misset JL; Jasmin C; Maral R; Mathé G
    Cancer Treat Rep; 1982 Oct; 66(10):1803-7. PubMed ID: 6982099
    [No Abstract]   [Full Text] [Related]  

  • 29. A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.
    Cavalli F; Klepp O; Renard J; Röhrt M; Alberto P
    Eur J Cancer (1965); 1981 Feb; 17(2):245-9. PubMed ID: 7262161
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
    Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
    Cancer Treat Rep; 1976 May; 60(5):633-5. PubMed ID: 1036468
    [No Abstract]   [Full Text] [Related]  

  • 31. [5-Fluorouracil(5-FU) in the treatment of adenocarcinomas of the digestive tract (apropos of 13 cases)].
    Vinhafs JC; Ferreira AJ
    Hospital (Rio J); 1967 Feb; 71(2):453-74. PubMed ID: 5302398
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
    Lokich J; Corkery J
    Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Etoposide: VP-16].
    Dicato M
    Bull Soc Sci Med Grand Duche Luxemb; 1982; 119(2):15-8. PubMed ID: 7160031
    [No Abstract]   [Full Text] [Related]  

  • 34. VP-16 and adriamycin in patients with advanced breast cancer.
    Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M
    Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
    Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E
    Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypersensitivity reactions induced by etoposide.
    O'Dwyer PJ; Weiss RB
    Cancer Treat Rep; 1984; 68(7-8):959-61. PubMed ID: 6744346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Panduro J; Hansen M; Hansen HH
    Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
    [No Abstract]   [Full Text] [Related]  

  • 38. Etoposide: a new anti-cancer agent.
    Arnold AM; Whitehouse JM
    Lancet; 1981 Oct; 2(8252):912-5. PubMed ID: 6117692
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
    Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
    Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
    [No Abstract]   [Full Text] [Related]  

  • 40. [Prospects of new chemotherapies].
    Sculier JP; Klastersky J
    Rev Med Brux; 1982 Oct; 3(8):519-27. PubMed ID: 6897459
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.